https://sciex.com/content/SCIEX/na/us/en

QTOF Technology for Targeted and Unknown Forensic Drugs Screening Workflows

Feb 22, 2016 | Blogs, Forensic | 0 comments

In this study, the Wisconsin State Laboratory of Hygiene (WSLH) outlines the comparison of their existing technology and how SCIEX LC-MS/MS systems can assist them in their forensic research. The WSLH routinely analyze for 300 forensic drug compounds in over 18,000 samples per year.

The highly laborious workflows they used to perform this routine analysis relied upon EMIT, HPLC (with wavelength detection) GC/NPD and GC-MS. The nature of the ever-changing forensic drug testing environment means that it is difficult to identify the widely varying synthetic cannabinoids and novel psychoactive substances. 

The purpose of this study was to investigate whether the adoption of QTOF technology for targeted and unknown forensic drugs screening workflows are sensitive and reliable to achieve these goals. The instrument of choice for this study was the TripleTOF® 5600+ system.

In the video below Adrian Taylor, Forensics Application Manager at SCIEX delivers an overview of the poster presentation for this study which was displayed at the annual TiAFT conference in Firenze, Italy. Download Poster >

Routine forensic drug testing has recently been given a boost with the launch of the X500R QTOF system, this system is designed specifically for routine forensic toxicology analysis. The X500R coupled with the brand new software application, SCIEX OS, delivers an all-encompassing solution for forensic drug screening. The intuitive workflows are ideally suited for the analysis of Synthetic Cannabinoids, Novel Psychoactive Substance. We have also produced a comprehensive library of compounds to assist with your analysis, this library contains over 1700 compounds with full acquired spectral data.

If your lab is using old technology, we want to hear from you. Tell us what kind of experiments you are running and what are the setbacks you have encountered?

Beyond mRNA: how advances in analytical techniques are enabling a revolution in the RNA drug landscape

Currently, there are 3 main types of in vitro transcribed (IVT) RNA drugs. Two of these—conventional messenger RNA (mRNA) and base-modified mRNA (bmRNA), which incorporates chemically modified nucleotides—are non-replicating. The third type is self-replicating RNA (srRNA), which is based on an engineered viral genome but devoid of viral structural protein genes. Its self-replicating ability makes srRNA a promising tool for new therapeutic drugs.

Changing the game of drug development with the Intabio ZT system

What better to learn how a new technology like icIEF-UV/MS is advancing drug development than hearing from the labs that are using it?

The whys behind the dos and don’ts of oligonucleotide analysis

We know that LC-MS oligonucleotide analysis can have its share of challenges—challenges with sensitivity, challenges with adduct formation and challenges with data analysis, to name just a few. That’s why this blog takes a closer look at the dos and don’ts of this type of analysis and explores some keys to success. It also explains why following these simple rules can vastly improve your oligonucleotide characterization and quantitation efficiency and success.

Posted by

0 Comments

Submit a Comment